KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Notes Payables (2024 - 2025)

Historic Notes Payables for NovoCure (NVCR) over the last 2 years, with Q3 2025 value amounting to $560.6 million.

  • NovoCure's Notes Payables rose 58.98% to $560.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $560.6 million, marking a year-over-year increase of 58.98%. This contributed to the annual value of $558.2 million for FY2024, which is N/A changed from last year.
  • According to the latest figures from Q3 2025, NovoCure's Notes Payables is $560.6 million, which was up 58.98% from $559.8 million recorded in Q2 2025.
  • Over the past 5 years, NovoCure's Notes Payables peaked at $560.6 million during Q3 2025, and registered a low of $557.3 million during Q3 2024.